Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Post by jopatcloon May 13, 2024 6:35am
108 Views
Post# 36036320

President of the AEPC Dr. Nico Blom with Hugh Nice photo

President of the AEPC Dr. Nico Blom with Hugh Nice photo Good comment

 @Synergy @Shotinthedark he said so much more than that: Ventripoint: The New Standard in Cardiac Imaging With VMS+4.0, we're not just following trends – we're setting them. Our technology stood out as a beacon of innovation and practicality, proving that we are at the forefront of medical technology.

Nice photo of Dr. Nico Blom with Hugh MacNaught !

the President of the AEPC, Dr. Nico Blom, 

Pediatric Cardiologist, President AEPC
Netherlands  Contact info


No alt text provided for this image
Post-Event Highlights from AEPC 2024 in Porto!

Ventripoint Diagnostics Ltd. Shines as the Star of the Show
What an exhilarating experience at AEPC 2024! We are immensely proud to have showcased our advanced AI-powered heart-scanning software, VMS+4.0, which became the talk of the conference. Thank you to everyone who joined us in Porto for your enthusiasm and engaging discussions.

Key Takeaways from AEPC 2024:
VMS Strain and Heat Maps: Our demonstrations highlighted how VMS+4.0’s visualization tools, especially the strain and heat maps, provide unparalleled insights into heart function. Cardiologists from around the globe were impressed by the precision and detail our software brings to cardiac diagnostics.

Automated Plotting of Key Anatomical Landmarks: Attendees experienced firsthand how VMS+4.0 simplifies and enhances cardiac assessments. The elimination of manual plotting not only streamlines the diagnostic process but also increases accuracy and reliability in volumetric measurements.

The feedback has been overwhelmingly positive, reinforcing our belief that VMS+4.0 will revolutionize cardiac care by making advanced diagnostics quicker and more accessible.

Moving Forward:
As we continue to await FDA approval, our resolve to deliver VMS+4.0 to healthcare providers worldwide has only strengthened. The interest and inquiries from international cardiologists and healthcare institutions at AEPC have been inspiring.

Ventripoint: The New Standard in Cardiac Imaging
With VMS+4.0, we're not just following trends – we're setting them. Our technology stood out as a beacon of innovation and practicality, proving that we are at the forefront of medical technology.

Thank you again for making us the star of AEPC 2024! We look forward to bringing our cutting-edge solutions to your hospitals and clinics.

Ventripoint HeartHealth MedicalInnovation AI FDA Cardiology AEPC2024 PostAEPC

Special thanks to the Ventripoint Diagnostics Ltd. team, the Angiopro GmbH team GmbH, the CardioLogic Ltd team, the President of the AEPC, Dr. Nico Blom, Dr. Kay Thorsten Laser, and the participants of the VMS+ workshop, Tineke Willems and so many others for their interest and time at our booth.

For ongoing updates or to get in touch, continue to follow our journey!

Dr. Nico Blom a
ExperienceExperience
Leiden University Medical Center logo
Pediatric CardiologistPediatric Cardiologist
Leiden University Medical Center and Academical Medical Center AmsterdamLeiden University Medical Center and Academical Medical Center Amsterdam
Oct 1994 - Present · 29 yrs 8 mosOct 1994 to Present · 29 yrs 8 mos
Association for European Paediatric and Congenital Cardiology - AEPC logo
Association for European Paediatric and Congenital Cardiology - AEPC
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities